Incyte Corp (NASDAQ: INCY) kicked off on Tuesday, up 0.26% from the previous trading day, before settling in for the closing price of $69.89. Over the past 52 weeks, INCY has traded in a range of $53.56-$83.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 14.46%. While this was happening, its average annual earnings per share was recorded 426.63%. With a float of $190.74 million, this company’s outstanding shares have now reached $193.78 million.
Let’s determine the extent of company efficiency that accounts for 2617 employees. In terms of profitability, gross margin is 92.28%, operating margin of 3.98%, and the pretax margin is 7.13%.
Incyte Corp (INCY) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Incyte Corp is 1.46%, while institutional ownership is 99.38%. The most recent insider transaction that took place on Jun 03 ’25, was worth 122,060. In this transaction EVP & General Counsel of this company sold 1,795 shares at a rate of $68.00, taking the stock ownership to the 26,504 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Officer proposed sale 1,795 for $68.00, making the entire transaction worth $122,060.
Incyte Corp (INCY) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 426.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 98.17% during the next five years compared to -40.36% drop over the previous five years of trading.
Incyte Corp (NASDAQ: INCY) Trading Performance Indicators
Take a look at Incyte Corp’s (INCY) current performance indicators. Last quarter, stock had a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.07. Likewise, its price to free cash flow for the trailing twelve months is 44.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.32, a number that is poised to hit 1.40 in the next quarter and is forecasted to reach 6.72 in one year’s time.
Technical Analysis of Incyte Corp (INCY)
Looking closely at Incyte Corp (NASDAQ: INCY), its last 5-days average volume was 1.84 million, which is a drop from its year-to-date volume of 1.91 million. As of the previous 9 days, the stock’s Stochastic %D was 80.18%. Additionally, its Average True Range was 1.95.
During the past 100 days, Incyte Corp’s (INCY) raw stochastic average was set at 70.56%, which indicates a significant decrease from 87.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 19.38% in the past 14 days, which was lower than the 35.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $61.90, while its 200-day Moving Average is $67.61.
